摘要
帕洛诺司琼是高选择性的第2代5-羟色胺3(5-HT3)受体拮抗药,具有高亲和力和长血浆消除半衰期(约40h)。临床试验证明,与传统5-HT3受体拮抗药相比,单剂量的帕洛诺司琼对急性化学治疗(化疗)性恶心呕吐的预防效果更优,其长效性对延迟性化疗性恶心呕吐也有良好的预防效果。研究发现,帕洛诺司琼对手术后恶心呕吐的预防作用也很显著。本文综述了帕洛诺司琼的药效学、药动学、适应证、临床试验、药物经济学等方面的研究进展。
Palonosetron is a highly selective second-generation 5-hydroxytryptamine type 3 （5-HTa） receptor antagonist （RA） with high binding affinity and long plasma elimination half-life （approximately 40 h）. Clinical trials demonstrated that compared with traditional 5-HT3 RAs, a single dose of palonosetron was more effective in preventing acute chemotherapy-induced nausea and vomiting （CINV） , and it also exhibited prolonged efficacy to provide significantly better protection from CINV in the delayed phases. It was indicated that palonosetron played an important role in preventing postoperative nausea and vomiting. The research progress of palonosetron, such as pharmacodynamics, pharmacokinetics, indication, clinical trials and pharmacoeconomics, is reviewed in the paper.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2009年第9期649-653,共5页
Chinese Journal of New Drugs and Clinical Remedies
关键词
血清素拮抗药
恶心
呕吐
手术后恶心呕吐
帕洛诺司琼
化疗性恶心呕吐
serotonin antagonists
nausea
vomiting
postoperative nausea and vomiting
palonosetron
chemotherapy-induced nausea and vomiting
